BiotechTube

EXC 001 + EXC 001 + EXC 001 + EXC 001

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Reduction in Hypertrophic Skin Scarring

Conditions

Reduction in Hypertrophic Skin Scarring

Trial Timeline

Jun 1, 2011 → Apr 16, 2012

NCT ID
NCT01346969

About EXC 001 + EXC 001 + EXC 001 + EXC 001

EXC 001 + EXC 001 + EXC 001 + EXC 001 is a phase 2 stage product being developed by Pfizer for Reduction in Hypertrophic Skin Scarring. The current trial status is completed. This product is registered under clinical trial identifier NCT01346969. Target conditions include Reduction in Hypertrophic Skin Scarring.

What happened to similar drugs?

2 of 2 similar drugs in Reduction in Hypertrophic Skin Scarring were approved

Approved (2) Terminated (1) Active (0)
✅Biktarvy 50Mg-200Mg-25Mg TabletGilead SciencesApproved
✅1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3%Omeros CorporationApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01346969Phase 2Completed

Competing Products

4 competing products in Reduction in Hypertrophic Skin Scarring

See all competitors
ProductCompanyStageHype Score
Biktarvy 50Mg-200Mg-25Mg TabletGilead SciencesApproved
43
EXC 001 (currently called PF-06473871)PfizerPhase 2
35
PF-06473871 + PF-06473871PfizerPhase 2
35
1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3%Omeros CorporationApproved
29